Strategic Blueprint LLC Reduces Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Strategic Blueprint LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,110 shares of the company’s stock after selling 586 shares during the quarter. Strategic Blueprint LLC’s holdings in Johnson & Johnson were worth $2,839,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in JNJ. Moneta Group Investment Advisors LLC grew its stake in Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Norges Bank purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth about $4,609,399,000. Morgan Stanley boosted its stake in shares of Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares during the last quarter. Barclays PLC boosted its stake in shares of Johnson & Johnson by 61.0% in the second quarter. Barclays PLC now owns 11,287,765 shares of the company’s stock worth $1,868,351,000 after buying an additional 4,278,512 shares during the last quarter. Finally, Imprint Wealth LLC boosted its stake in shares of Johnson & Johnson by 17,087.7% in the second quarter. Imprint Wealth LLC now owns 2,913,480 shares of the company’s stock worth $291,348,000 after buying an additional 2,896,529 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $147.52 on Friday. Johnson & Johnson has a 1-year low of $144.95 and a 1-year high of $175.97. The company has a market cap of $355.49 billion, a PE ratio of 10.68, a price-to-earnings-growth ratio of 2.50 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The stock’s 50 day simple moving average is $157.24 and its 200-day simple moving average is $155.98.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The firm had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm’s revenue was down 9.7% compared to the same quarter last year. During the same quarter last year, the business posted $2.35 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on JNJ shares. Morgan Stanley lowered their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 28th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, March 13th. Finally, Raymond James raised their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $177.31.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.